Sutro Biopharma (STRO) Total Debt (2017 - 2023)

Sutro Biopharma's Total Debt history runs 7 years deep, the most recent figure standing at $4.1 million for Q4 2023.

• In Q4 2023, Total Debt fell 75.04% year-over-year to $4.1 million; the TTM figure through Dec 2023 stood at $4.1 million (down 75.04% YoY), while the FY2023 annual figure was $4.1 million, down 75.04% from the prior year.
• Total Debt came in at $4.1 million for Q4 2023 at Sutro Biopharma, down from $7.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $25.3 million in Q1 2022 to a low of $4.1 million in Q4 2023.
• A 5-year average of $18.1 million and a median of $20.8 million in 2022 frame the typical range for Total Debt.
• Across the five-year window, Total Debt surged 148.53% in 2020 and sank 75.04% in 2023, its largest moves.
• Sutro Biopharma's Total Debt stood at $9.9 million in 2019, then soared by 148.53% to $24.5 million in 2020, then advanced by 2.31% to $25.1 million in 2021, then tumbled by 35.21% to $16.3 million in 2022, then tumbled by 75.04% to $4.1 million in 2023.
• According to Business Quant data, Total Debt over the past three periods registered $4.1 million, $7.1 million, and $10.2 million for Q4 2023, Q3 2023, and Q2 2023 respectively.

Peer Comparison